Phase 1 N=60 Praziquantel Bioequivalence Study
Healthy
Primary: Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of L-Praziquantel (L-PZQ) — 441.53; 547.41; 460.25 Hour*nanogram…
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=161 Efficacy and Safety Study of Pitavastatin Compared to atoRvastatin in Type 2 dIabeTes Mellitus With Hypercholesterolemia
Hypercholesterolemia With Type2DM
Primary: Proportion of Patients Achieving LDL- C<100mg/dL — 61; 54 Participants
Phase 3 N=400 NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed
Malignant Pleural Mesothelioma
Primary: Overall Survival (OS) — 8.5; 8.0 months — p=0.58
Phase 2 N=26 Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children
HIV Infections
Primary: Termination From Treatment Due to a Suspected Adverse Drug Reaction (SADR) — 1; 0; 10; 4 Participants
N/A N=41 Transcutaneous Electrical Nerve Stimulation (TENS) and Head and Neck Cancer Pain (HNC) (TENS & HNC)
Head Cancer · Neck Cancer · Pain
Primary: Change in Pain Intensity in Head/Neck Cancer Area: 10cm Visual Analog Scale (VAS) — -1.4; -0.6; 0.1 change units on a VAS scale
N/A N=9 Fusion Targeted Biopsy of the Prostate
Prostate Cancer
Primary: Cancer Detection by Targeted and Standard Biopsy Approaches
Phase 4 N=267 Examining Tolerance to CNS Stimulants in ADHD
Attention-deficit/Hyperactivity Disorder
Primary: Number of Dose Changes Required Per Protocol — 1.79; 1.61 Number of Increases
N/A N=38 Study to Evaluate the Effect of Nicotinamide Riboside on Immunity
Atherosclerosis · Diabetes · Coronary Artery Disease
Primary: Mean IL-1 Beta Release From Peripheral Blood Mononuclear Cells During Refeeding After 24 Hour Fast — 582; 794 mg/dL
Phase 2 N=58 Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Fallopian Tube Clear Cell Adenocarcinoma · Fallopian Tube Endometrioid Adenocarcinoma · Fallopian Tube Mucinous Adenocarcinoma
Primary: Proportion of Participants With Objective Response — 0.196 Proportion of participants
N/A N=131 Effect of Chair Yoga on Elders With Osteoarthritis
Osteoarthritis (OA)
Primary: PROMIS Pain Interference — 19.0; 19.1; 18.0; 17.5 score on a scale
Phase 4 N=32 Nicotine Patch as an Adjunctive Intervention to Reduce Secondhand Smoke Among NICU Families
Environmental Tobacco Smoke · Smoking Cessation
Primary: Feasibility as Assessed by Number of Participants Who Accepted NRT Patches From Research Staff. — 13 Participants
N/A N=150 Utility of Ultrasound in Identification of Midline and Placement of Epidural in Severely Obese Parturients
Epidural Anesthesia · Spinal Ultrasound · Obesity
Primary: Time for Epidural Placement — 9.0; 6.2 minutes
Phase 3 N=132 Modified Dakin's Solution in Reducing Radiation-Induced Dermatitis in Patients With Head and Neck Cancer Undergoing Radiation Therapy
Head and Neck Carcinoma · Radiation-Induced Dermatitis
Primary: Radiation Dermatitis — 34; 36 Participants — p=.8872
Phase 2 N=77 Phase II Confirmatory Study in Erythropoietic Protoporphyria (EPP)
Erythropoietic Protoporphyria
Primary: Time in Direct Sunlight Between 10:00-15:00 on Pain-free Days — 8.25; 0.75 Hours
Phase 3 N=83 Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) in Japanese Participants With Complicated Intra-abdominal Infection or Complicated Urinary Tract Infection (MK-7655A-017)
Complicated Intra-abdominal Infection · Complicated Urinary Tract Infection
Primary: Percentage of Participants Experiencing ≥1 Adverse Events (AE) — 74.1 Percentage of Participants